



Supplementary Figure 2. Kaplan–Meier analysis of overall survival depending on the types of third-line treatment. (A) Lenvatinib-unmatched patients. (B) Lenvatinib-PS-matched patients. (C) Sorafenib-unmatched patients. (D) Sorafenib-PS-matched patients.